Taplitumomab paptox

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameTaplitumomab paptox
Drug Alias NameB43 (anti-CD19) immunotoxinB43-PAPMonoclonal antibody B43-PAP conjugate
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody
Mechanisms of ActionB-lymphocyte antigen CD19 inhibitors
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsLeukemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Minnesota
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUniversity Of Minnesota
Active IndicationsN/A
Inactive IndicationsLeukemia

Other Information

ATC CodeN/A
Related LinksN/A